# Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
Canonical URL: https://biopharmsignal.com/news/CNTX/context-therapeutics-announces-positive-interim-efficacy-and-safety-results-from-ongoing-phase-1-clinical-trial-for-ctim-76
Ticker: CNTX
Company: Context Therapeutics
Source: Context Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.contexttherapeutics.com
## Summary

29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer (“PROC”) who progressed on a median of 7 prior lines of therapy Cytokine Release Syndrome (“CRS”) in PROC limited to Grade 1 in 11% of patients Pharmacokinetic (“ PK”) profile supports exploration

## Article Body
29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer (“PROC”) who progressed on a median of 7 prior lines of therapy Cytokine Release Syndrome (“CRS”) in PROC limited to Grade 1 in 11% of patients Pharmacokinetic (“ PK”) profile supports exploration
## Recent Company News
- 2026-06-25 13:46 EST — [Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76](https://biopharmsignal.com/news/CNTX/context-therapeutics-announces-positive-interim-efficacy-and-safety-results-from-ongoing-phase-1-clinical-trial-for-ctim-76) — Source: Context Therapeutics
- 2026-06-25 13:46 EST — [Context Therapeutics to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/CNTX/context-therapeutics-to-present-at-the-jefferies-global-healthcare-conference) — Source: Context Therapeutics
- 2026-06-25 13:46 EST — [Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202](https://biopharmsignal.com/news/CNTX/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202) — Source: Context Therapeutics
- 2026-06-25 13:46 EST — [Context Therapeutics Reports First Quarter 2026 Operating and Financial Results](https://biopharmsignal.com/news/CNTX/context-therapeutics-reports-first-quarter-2026-operating-and-financial-results) — Source: Context Therapeutics
- 2026-06-25 13:46 EST — [Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/CNTX/context-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4) — Source: Context Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)